Simulations Plus (NASDAQ: SLP) — Perfil da empresa, notícias e dados financeiros
Simulations Plus creates simulation software for pharmaceutical R&D, aimed at advancing drug discovery with high predictive accuracy.
Simulations Plus
Simulations Plus (NASDAQ:SLP) specializes in creating simulation and modeling software for pharmaceutical research and development. With a focus on advancing drug discovery and development, the company offers a suite of software products designed to predict properties of molecules with high accuracy. These solutions enable researchers and biotech companies to make more informed decisions earlier in the drug development process, reducing time and costs associated with bringing new therapies to market. Simulations Plus also provides consulting services, leveraging its software capabilities to offer customized solutions that meet the specific needs of its clients. The company's objective is to remain at the forefront of technological innovation, continuously improving its offerings to support the evolving needs of the global pharmaceutical industry.
Resumo
Operações
Produtos e/ou serviços de Simulations Plus
- GastroPlus® - software for the simulation of pharmacokinetics, pharmacodynamics, and drug absorption.
- ADMET Predictor® - a tool for predicting the absorption, distribution, metabolism, excretion, and toxicity of chemicals.
- DILIsym® - software for predicting drug-induced liver injury, aiding in the assessment of drug safety.
- Kibos® - an AI-driven platform for clinical trial simulation and prediction, enhancing drug development strategies.
- MonolixSuite® - a comprehensive solution for pharmacometric analyses, including population PK/PD modeling.
- MembranePlus™ - software for simulating and predicting oral drug absorption and formulation performance.
equipe executiva do Simulations Plus
- Shawn M. O'ConnorChief Executive Officer
- William FrederickCFO, Executive VP & Corporate Secretary
- Joshua FoheyChief Operating Officer
- John Anthony DiBellaChief Revenue Officer
- Jill Fiedler-KellyPresident of Services Solutions
- Steven ChangGlobal Head of Strategic Alliances
Comunicados recentes
O que a Simulations Plus (SLP) comunicou ao mercado, do mais recente para o mais antigo.
- NEWS_HALT halt | SLPFato relevante
Histórico de dividendos
Dividendos por ação pagos pela Simulations Plus, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2024 | — | — | — | $0.2400 |
| FY2023 | — | — | — | $0.2400 |
| FY2022 | — | — | — | $0.2400 |
| FY2021 | — | — | — | $0.2400 |
| FY2020 | — | — | — | $0.2400 |
Principais indicadores financeiros
Resultados divulgados pela Simulations Plus, em USD.
- Cap. de mercado
- 374,2 mi
- Receita (TTM)
- 82,1 mi
- P/L
- 46.3
- LPA (diluído, TTM)
- 0.4
- Dividend yield
- —
- Margem de lucro
- 9.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 79,2 mi | -70,7 mi | -64,7 mi | |
| 70 mi | 6,1 mi | 10 mi | |
| 59,6 mi | 8,7 mi | 10 mi | |
| 53,9 mi | 14,9 mi | 12,5 mi |